Advertisement

Prognostic Impact of Statins on Patients With Peripheral Artery Disease With Elevated C-Reactive Protein Levels

Published:October 15, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.09.018
      This study aimed to elucidate the prognostic influence of statins in relation to the degree of inflammation at the time of endovascular therapy (EVT) for patients with peripheral artery disease (PAD). This observational study included patients with PAD who underwent EVT, including 285 statin users and 275 statin non-users. They were assigned into four groups depending on C-reactive protein (CRP) level at the time of EVT: low CRP (<0.1 mg/dL), intermediate-low CRP (0.1-0.3 mg/dL), intermediate-high CRP (0.3-1.0 mg/dL), and high CRP (>1.0 mg/dL). A composite of death and major amputation as the primary endpoint was compared between statin users and non-users in each CRP category. Overall, statin users showed a lower event rate than non-users (log-rank, p=0.02). However, the event rates did not differ significantly between statin users and non-users in the low, intermediate-low, and intermediate-high CRP categories. In the high CRP category, statin users showed a lower event rate than non-users (p=0.002). In this population, multivariate Cox regression analysis revealed that statin use was independently associated with the primary endpoint (hazard ratio: 0.28 [95% confidence interval: 0.14-0.55]). Statins may exert favorable prognostic effects in PAD patients with highly elevated CRP levels, but not in those with low-to-moderate CRP levels.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Heart Protection Study Collaborative Group
        Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
        Lancet. 2011; 378: 2013-2020
        • Kumbhani DJ
        • Steg PG
        • Cannon CP
        • Eagle KA
        • Smith Jr, SC
        • Goto S
        • Ohman EM
        • Elbez Y
        • Sritara P
        • Baumgartner I
        • Banerjee S
        • Creager MA
        • Bhatt DL
        • REACH Registry Investigators
        Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.
        Eur Heart J. 2014; 35: 2864-2872
        • Gerhard-Herman MD
        • Gornik HL
        • Barrett C
        • Barshes NR
        • Corriere MA
        • Drachman DE
        • Fleisher LA
        • Fowkes FGR
        • Hamburg NM
        • Kinlay S
        • Lookstein R
        • Misra S
        • Mureebe L
        • Olin JW
        • Patel RAG
        • Regensteiner JG
        • Schanzer A
        • Shishehbor MH
        • Stewart KJ
        • Treat-Jacobson D
        • Walsh ME
        • Halperin JL
        • Levine GN
        • Al-Khatib SM
        • Birtcher KK
        • Bozkurt B
        • Brindis RG
        • Cigarroa JE
        • Curtis LH
        • Fleisher LA
        • Gentile F
        • Gidding S
        • Hlatky MA
        • Ikonomidis J
        • Joglar J
        • Pressler SJ
        • Wijeysundera DN.
        AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary.
        Vasc Med. 2016; 22 (2017): Np1-N43
        • Aboyans V
        • Ricco JB
        • Bartelink MEL
        • Björck M
        • Brodmann M
        • Cohnert T
        • Collet JP
        • Czerny M
        • De Carlo M
        • Debus S
        • Espinola-Klein C
        • Kahan T
        • Kownator S
        • Mazzolai L
        • Naylor AR
        • Roffi M
        • Röther J
        • Sprynger M
        • Tendera M
        • Tepe G
        • Venermo M
        • Vlachopoulos C
        • Desormais I.
        2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS).
        Eur Heart J. 2018; 39: 763-816
        • Hansson GK.
        Inflammation, atherosclerosis, and coronary artery disease.
        N Engl J Med. 2005; 352: 1685-1695
        • Ridker PM
        • Hennekens CH
        • Buring JE
        • Rifai N.
        C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
        N Engl J Med. 2000; 342: 836-843
        • Ridker PM
        • Cushman M
        • Stampfer MJ
        • Tracy RP
        • Hennekens CH.
        Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
        N Engl J Med. 1997; 336: 973-979
        • Taleb S.
        Inflammation in atherosclerosis.
        Arch Cardiovasc Dis. 2016; 109: 708-715
        • Ridker PM
        • Rifai N
        • Rose L
        • Buring JE
        • Cook NR.
        Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
        N Engl J Med. 2002; 347: 1557-1565
        • Nissen SE
        • Tuzcu EM
        • Schoenhagen P
        • Crowe T
        • Sasiela WJ
        • Tsai J
        • Orazem J
        • Magorien RD
        • O'Shaughnessy C
        • Ganz P
        • Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators
        Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
        N Engl J Med. 2005; 352: 29-38
        • Singh TP
        • Morris DR
        • Smith S
        • Moxon JV
        • Golledge J.
        Systematic review and meta-analysis of the association Between C-reactive protein and major cardiovascular events in patients with peripheral artery disease.
        Eur J Vasc Endovasc Surg. 2017; 54: 220-233
        • Liao JK.
        Isoprenoids as mediators of the biological effects of statins.
        J Clin Invest. 2002; 110: 285-288
        • Ridker PM.
        A test in context: high-sensitivity C-reactive protein.
        J Am Coll Cardiol. 2016; 67: 712-723
        • Stevens PE
        • Levin A
        • Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members
        Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.
        Ann Intern Med. 2013; 158: 825-830
        • Baigent C
        • Blackwell L
        • Emberson J
        • Holland LE
        • Reith C
        • Bhala N
        • Peto R
        • Barnes EH
        • Keech A
        • Simes J
        • Collins R.
        • Cholesterol Treatment Trialists’ (CTT) Collaboration
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Arya S
        • Khakharia A
        • Binney ZO
        • DeMartino RR
        • Brewster LP
        • Goodney PP
        • Wilson PWF.
        Association of statin dose with amputation and survival in patients with peripheral artery disease.
        Circulation. 2018; 137: 1435-1446
        • Albert MA
        • Danielson E
        • Rifai N
        • Ridker PM
        • PRINCE Investigators
        Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
        JAMA. 2001; 286: 64-70
        • Diamantis E
        • Kyriakos G
        • Quiles-Sanchez LV
        • Farmaki P
        • Troupis T.
        The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature.
        Curr Cardiol Rev. 2017; 13: 209-216